US10196360B2 - Crystal forms of bedaquiline fumarate and preparation methods therefor - Google Patents

Crystal forms of bedaquiline fumarate and preparation methods therefor Download PDF

Info

Publication number
US10196360B2
US10196360B2 US15/760,090 US201515760090A US10196360B2 US 10196360 B2 US10196360 B2 US 10196360B2 US 201515760090 A US201515760090 A US 201515760090A US 10196360 B2 US10196360 B2 US 10196360B2
Authority
US
United States
Prior art keywords
crystal form
bedaquiline fumarate
fumarate
bedaquiline
filtered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US15/760,090
Other languages
English (en)
Other versions
US20180265473A1 (en
Inventor
Jinyi Xu
Liang Zhang
Xiangyang Zhang
Xinzeng Wang
Jian Chai
Hongying LUO
Zhiqing Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Hisun Pharmaceutical Co Ltd
Original Assignee
Zhejiang Hisun Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Hisun Pharmaceutical Co Ltd filed Critical Zhejiang Hisun Pharmaceutical Co Ltd
Assigned to ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. reassignment ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ZHANG, XIANGYANG, YANG, Zhiqing, WANG, Xinzeng, CHAI, Jian, LUO, Hongying, XU, Jinyi, ZHANG, LIANG
Publication of US20180265473A1 publication Critical patent/US20180265473A1/en
Application granted granted Critical
Publication of US10196360B2 publication Critical patent/US10196360B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/0063—Control or regulation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the present invention relates to the field of pharmacy. More specifically, the present invention relates to new crystal forms of bedaquiline fumarate and the preparation methods thereof.
  • Bedaquiline fumarate is a new type of anti-tuberculosis drugs, is a biaryl quinoline antibiotics, bactericide for the Mycobacterium tuberculosis , the main mechanism of action of bedaquiline fumarate is to inhibit the synthase of adenosine triphosphate (ATP) of Mycobacterium tuberculosis , block the energy supply of bacteria.
  • Bedaquiline has the same bactericidal activity against the common and drug resistant (including multidrug-resistant) strains of Mycobacterium tuberculosis , is not cross-resistant to existing antituberculosis drugs and is equally effective against dormant bacteria.
  • bedaquiline fumarate (1R,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-dimethylamino-1-phenyl-2-(1-naphthyl)-2-butan of fumarate, the structural formula is:
  • crystal forms may have different physicochemical properties including melting point, chemical stability, apparent solubility, dissolution rate, optical and mechanical properties, which directly affect the quality of the drug substance and the formulation.
  • the present invention relates to new crystal forms of bedaquiline fumarate, namely crystal form I, crystal form II and crystal form III.
  • One of the objects of the present invention is to provide crystal form I of bedaquiline fumarate.
  • the X-ray powder diffraction pattern of the crystal form I of bedaquiline fumarate provided by the present invention has characteristic peaks at 2 ⁇ (°) values of 5.6 ⁇ 0.2, 11.2 ⁇ 0.2, 22.6 ⁇ 0.2, 23.1 ⁇ 0.2, 23.6 ⁇ 0.2, 29.0 ⁇ 0.2.
  • X-ray powder diffraction pattern of the crystal form I of bedaquiline fumarate provided by the present invention also has characteristic peaks at 2 ⁇ (°) values of 3.8 ⁇ 0.2, 16.9 ⁇ 0.2, 18.8 ⁇ 0.2, 19.3 ⁇ 0.2, 20.6 ⁇ 0.2, 20.9 ⁇ 0.2, 21.9 ⁇ 0.2, 26.7 ⁇ 0.2, 28.3 ⁇ 0.2.
  • the X-ray powder diffraction pattern of the crystal form I of bedaquiline fumarate provided by the present invention has 2 ⁇ , d( ⁇ ) and relative intensity data as shown in the following Table 1:
  • the crystal form I of bedaquiline fumarate of the present invention has an X-ray powder diffraction pattern as shown in FIG. 1 .
  • the molecular stereoscopic projection of the crystal form I of bedaquiline fumarate of the present invention is shown in FIG. 2 .
  • the unit cell accumulation projection of the crystal form I of bedaquiline fumarate of the present invention along the b axis is shown in FIG. 3 .
  • the crystal form I of bedaquiline fumarate of the present invention can be characterized by the infrared absorption spectrum measured by KBr pellet, it has characteristic peaks at about 3408.88 cm ⁇ 1 ⁇ 2 cm ⁇ 1 , 2643.66 cm ⁇ 1 ⁇ 2 cm ⁇ 1 , 1653.53 cm ⁇ 1 ⁇ 2 cm ⁇ 1 , 1314.86 cm ⁇ 1 ⁇ 2 cm ⁇ 1 , 1271.71 cm ⁇ 1 ⁇ 2 cm ⁇ 1 , 864.48 cm ⁇ 1 ⁇ 2 cm ⁇ 1 , 787.56 cm ⁇ 1 ⁇ 2 cm ⁇ 1 .
  • the infrared absorption spectrum of the crystal form I of bedaquiline fumarate has characteristic peaks at about 3408.02 cm ⁇ 1 ⁇ 2 cm ⁇ 1 , 3051.07 cm ⁇ 1 ⁇ 2 cm ⁇ 1 , 2945.75 cm ⁇ 1 ⁇ 2 cm ⁇ 1 , 2895.89 cm ⁇ 11 ⁇ 2 cm ⁇ 1 , 2643.66 cm ⁇ 1 ⁇ 2 cm ⁇ 1 , 2466.88 cm ⁇ 1 ⁇ 2 cm ⁇ 1 , 1701.54 cm ⁇ 1 ⁇ 2 cm ⁇ 1 , 1653.53 cm ⁇ 1 ⁇ 2 cm ⁇ 1 , 1617.64 cm ⁇ 1 ⁇ 2 cm ⁇ 1 , 1597.35 cm ⁇ 1 ⁇ 2 cm ⁇ 1 , 1568.56 cm ⁇ 1 ⁇ 2 cm ⁇ 1 , 1511.54 cm ⁇ 1 ⁇ 2 cm ⁇ 1 , 1489.43 cm ⁇ 1 ⁇ 2 cm ⁇ 1 , 1458.54 cm ⁇ 1
  • the infrared spectrum of the crystal form I of bedaquiline fumarate is shown in FIG. 4 .
  • the differential scanning calorimetry (DSC) thermogram of the crystal form I of bedaquiline fumarate of the present invention has a maximum absorption peak within the range of 205-210° C.
  • the DSC thermogram of the crystal form I of bedaquiline fumarate of the present invention is shown in FIG. 5 .
  • the TGA thermogram of the crystal form I of bedaquiline fumarate of the present invention is shown in FIG. 6 .
  • Another object of the present invention is to provide crystal form II of bedaquiline fumarate.
  • the X-ray powder diffraction pattern of the crystal form II of bedaquiline fumarate provided by the present invention has characteristic peaks at 2 ⁇ (°) values of 4.7 ⁇ 0.2, 7.4 ⁇ 0.2, 9.6 ⁇ 0.2, 16.5 ⁇ 0.2, 16.8 ⁇ 0.2, 18.7 ⁇ 0.2, 19.9 ⁇ 0.2, 21.5 ⁇ 0.2, 21.9 ⁇ 0.2, 24.3 ⁇ 0.2.
  • X-ray powder diffraction pattern of the crystal form II of bedaquiline fumarate provided by the present invention has characteristic peaks at 2 ⁇ (°) values of 3.4 ⁇ 0.2, 8.4 ⁇ 0.2, 11.6 ⁇ 0.2, 12.6 ⁇ 0.2, 14.9 ⁇ 0.2, 20.3 ⁇ 0.2.
  • the X-ray powder diffraction pattern of the crystal form II of bedaquiline fumarate f the present invention has 2 ⁇ , d( ⁇ ) and relative intensity data as shown in the following Table 2:
  • the crystal form II of bedaquiline fumarate of the present invention has an X-ray powder diffraction pattern as shown in FIG. 7 .
  • the crystal form II of bedaquiline fumarate of the present invention can be characterized by the infrared absorption spectrum measured by KBr pellet, it has characteristic peaks at about 3408.88 cm ⁇ 1 ⁇ 2 cm ⁇ 1 , 2643.66 cm ⁇ 1 ⁇ 2 cm ⁇ 1 , 1721.80 cm ⁇ 1 ⁇ 2 cm ⁇ 1 , 1314.86 cm ⁇ 1 +2 cm ⁇ 1 , 865.79 cm ⁇ 1 ⁇ 2 cm ⁇ 1 , 776.91 cm ⁇ 1 ⁇ 2 cm ⁇ 1 .
  • the infrared spectrum of the crystal form II of bedaquiline fumarate is shown in FIG. 8 .
  • the differential scanning calorimetry (DSC) thermogram of the crystal form II of bedaquiline fumarate of the present invention has a maximum absorption peak within the range of 205-210° C.
  • the DSC thermogram of the crystal form II of bedaquiline fumarate of the present invention is shown in FIG. 9 .
  • the TGA thermogram of the crystal form II of bedaquiline fumarate of the present invention is shown in FIG. 10 .
  • Another object of the present invention is to provide crystal form III of bedaquiline fumarate.
  • the X-ray powder diffraction pattern of the crystal form III of bedaquiline fumarate provided by the present invention has characteristic peaks at 2 ⁇ (°) values of 6.1 ⁇ 0.2, 10.4 ⁇ 0.2, 12.0 ⁇ 0.2, 14.1 ⁇ 0.2, 16.9 ⁇ 0.2, 18.9 ⁇ 0.2, 20.5 ⁇ 0.2, 20.8 ⁇ 0.2, 21.5 ⁇ 0.2, 23.2 ⁇ 0.2.
  • X-ray powder diffraction pattern of the crystal form III of bedaquiline fumarate provided by the present invention has characteristic peaks at 2 ⁇ (°) values of 13.2 ⁇ 0.2, 19.3 ⁇ 0.2, 20.0 ⁇ 0.2, 24.9 ⁇ 0.2, 26.9 ⁇ 0.2, 27.3 ⁇ 0.2.
  • the X-ray powder diffraction pattern of the crystal form III of bedaquiline fumarate of the present invention has 2 ⁇ , d( ⁇ ) and relative intensity data as shown in the following Table 3:
  • the crystal form III of bedaquiline fumarate of the present invention has an X-ray powder diffraction pattern as shown in FIG. 11 .
  • the crystal form III of bedaquiline fumarate of the present invention can be characterized by the infrared absorption spectrum measured by KBr pellet, it has characteristic peaks at about 1700.95 cm ⁇ 1 ⁇ 2 cm ⁇ 1 , 1636.91 cm ⁇ 1 ⁇ 2 cm ⁇ 1 , 1597.23 cm ⁇ 1 ⁇ 2 cm ⁇ 1 , 1563.58 cm ⁇ 1 +2 cm ⁇ 1 , 1490.53 cm ⁇ 1 ⁇ 2 cm ⁇ 1 , 1459.10 cm ⁇ 1 ⁇ 2 cm ⁇ 1 , 1392.58 cm ⁇ 1 ⁇ 2 cm ⁇ 1 , 1342.09 cm ⁇ 1 ⁇ 2 cm ⁇ 1 , 1251.42 cm ⁇ 1 ⁇ 2 cm ⁇ 1 , 1168.11 cm ⁇ 1 ⁇ 2 cm ⁇ 1 , 1059.74 cm ⁇ 1 ⁇ 2 cm ⁇ 1 , 922.20 cm ⁇ 1 ⁇ 2 cm ⁇ 1 .
  • the infrared spectrum of the crystal form III of bedaquiline fumarate is shown in FIG. 12 .
  • the differential scanning calorimetry (DSC) thermogram of the crystal form III of bedaquiline fumarate of the present invention has a maximum absorption peak within the range of 205-207° C.
  • the DSC thermogram of the crystal form III of bedaquiline fumarate of the present invention is shown in FIG. 13 .
  • the TGA thermogram of the crystal form III of bedaquiline fumarate of the present invention is shown in FIG. 14 .
  • Another object of the present invention is to provide a method for preparing crystal form I of bedaquiline fumarate comprising the following steps:
  • the weight-to-volume ratio of bedaquiline fumarate to the mixed solvent of methanol and water is 1:10-50 g/ml, preferably 1:10-20 g/ml; the volume percentage of water is preferably 10%-70%, more preferably 20%-40%.
  • Another object of the present invention is to provide a method for preparing crystal form II of bedaquiline fumarate comprising the following steps:
  • (1)(1R,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-dimethylamino-1-phenyl-2-(1-naphthyl)-2-butanol fumarate is dissolved in a mixed solvent of methanol and ethyl acetate or a mixed solvent of methanol and ethanol;
  • the weight-to-volume ratio of bedaquiline fumarate to the mixed solvent of methanol and ethyl acetate is 1:1-20 g/ml, preferably 1:5-10 g/ml; the volume percentage of methanol in the mixed solvent is 40%-99%, preferably 50%-70%.
  • the weight-to-volume ratio of bedaquiline fumarate to the mixed solvent of methanol and ethanol is 1:1-20 g/ml, preferably 1:5-15 g/ml; the volume percentage of methanol in the mixed solvent is 40%-80%, preferably 50%-60%.
  • a further object of the present invention is to provide a method for preparing crystal form III of bedaquiline fumarate comprising the following steps:
  • the X-ray powder diffractometer (XRPD) and the test conditions involved in the present invention are: X-ray powder diffractometer model Rigaku D/max-2200 Cu target; operation method: scanning speed 4°/min, scanning step width 0.01°.
  • the infrared spectrophotometer and the test conditions involved in the present invention are: infrared spectrophotometer model: BRWKER VECTOR 22; operation method: using KBr pellet method, scanning range 400-4000 cm ⁇ 1 .
  • test conditions for DSC involved in the present invention are: differential scanning calorimeter model: NETZSCH DSC200 F3 Maia; operation method: heating rate 10° C./min, temperature range: 30° C.-250° C.
  • test conditions for TGA involved in the present invention are: thermogravimetric analyzer model: PerkinElmer TGA400; operation method: heating rate 10° C./min, temperature range: 30° C.-300° C.
  • the test conditions for the particle size involved in the present invention are: Mastersizer model: Mastersizer 2000; operation method: 20 mg of bedaquiline fumarate sample is taken, about 5.0 ml dispersant (n-hexane) is added, the sample is subjected to ultrasonication for 1.0 min, is allowed to stabilize for 0.5-1.0 min and then is tested.
  • test conditions for liquid chromatography involved in the present invention are: chromatographic column: Ultimate AQ C18, 250 ⁇ 4.6 mm, 5 ⁇ m; mobile phase A: acetonitrile and 0.1% trifluoroacetic acid, mobile phase B: water and 0.1% trifluoroacetic acid; detection wavelength: 220 nm; flow rate: 1 ml/min; injection volume: 10 ⁇ l.
  • the inventors of the present invention found that the new crystal forms of bedaquiline fumarate successfully improve the deficiencies of the prior art, and the drugs comprising the crystal forms of the present invention have the advantages of high purities and excellent physical and chemical properties, good stability, the crystallization methods thereof can effectively improve product quality and can be effectively used in the preparation of drugs and large-scale production and so on.
  • FIG. 1 is an X-ray powder diffraction pattern of crystal form I of bedaquiline fumarate obtained in Example 1.
  • FIG. 2 is molecular stereoscopic projection of crystal form I of bedaquiline fumarate obtained in Example 1.
  • FIG. 3 is the unit cell accumulation projection of crystal form I of bedaquiline fumarate obtained in Example 1 along the b axis.
  • FIG. 4 is an infrared absorption spectrum of crystal form I of bedaquiline fumarate obtained in Example 1.
  • FIG. 5 is a DSC thermogram of crystal form I of bedaquiline fumarate obtained in Example 1.
  • FIG. 6 is a TGA thermogram of crystal form I of bedaquiline fumarate obtained in Example 1.
  • FIG. 7 is an X-ray powder diffraction pattern of crystal form II of bedaquiline fumarate obtained in Example 6.
  • FIG. 8 is an infrared absorption spectrum of crystal form II of bedaquiline fumarate obtained in Example 6.
  • FIG. 9 is a DSC thermogram of crystal form II of bedaquiline fumarate obtained in Example 6.
  • FIG. 10 is a TGA thermogram of crystal form II of bedaquiline fumarate obtained in Example 6.
  • FIG. 11 is an X-ray powder diffraction pattern of crystal form III of bedaquiline fumarate obtained in Example 12.
  • FIG. 12 is an infrared absorption spectrum of crystal form III of bedaquiline fumarate obtained in Example 12.
  • FIG. 13 is a DSC thermogram of crystal form III of bedaquiline fumarate obtained in Example 12.
  • FIG. 14 is a TGA thermogram of crystal form III of bedaquiline fumarate obtained in Example 12.
  • the crystal form I, crystal form II and crystal form III of bedaquiline fumarate prepared respectively in Example 1, Example 6 and Example 12 of the present invention were selected for test of particle size.
  • Test Procedure the Hydro2000SM injector was connected and the Small Volume Sample Dispersion Unit tachometer was turned on, then a suitable amount of ethanol was added to the sample cell to clean the detection channel of the instrument.
  • a suitable amount of n-hexane (dispersant) was added to the dispersion cup, a suitable amount of n-hexane (dispersant) was inlet into the instrument to exhaust gas, the stirring rate was set to 2950 rpm, optical correction and background measurement were carried out.
  • the suspension was added to the sample cell until the opacity was between 15% to 20%, the suspension was allowed to stabilize for 0.5-1.0 min, the measurement time was 4 sec, the test results was saved automatically by the system.
  • the test results show that the particle sizes of the crystal form I and crystal form II of bedaquiline fumarate were smaller than that of the crystal form III.
  • the smaller the particle size, the bigger the specific surface area, and bigger specific surface area was conducive to improving the dissolution behavior, and the improved dissolution behavior was considered to improve the bioavailability.
  • the particles of the three crystal forms were dispersed homogeneously, in the actual production, a step of micronization or screening process was reduced and costs were saved.
  • Table 6 shows the solubility data of the different crystal forms prepared in the present invention in different solvents at 50° C.
  • the crystal form I, the crystal form II and the crystal form III of bedaquiline fumarate prepared respectively in Example 1, Example 6 and Example 12 of the present invention were selected for solubility test.
  • Table 7 shows the test results of stability by liquid chromatography of the different crystal forms prepared according to the present invention at a temperature of 60° C. and a humidity of 75% for 6 months.
  • Example 1 The crystal form I, the crystal form II and the crystal form III of bedaquiline fumarate prepared respectively in Example 1, Example 6 and Example 12 of the present invention were selected for liquid chromatography test.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
US15/760,090 2015-10-20 2015-10-20 Crystal forms of bedaquiline fumarate and preparation methods therefor Active US10196360B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2015/092343 WO2017066926A1 (fr) 2015-10-20 2015-10-20 Formes cristallines de fumarate de bédaquiline et leurs procédés de préparation

Publications (2)

Publication Number Publication Date
US20180265473A1 US20180265473A1 (en) 2018-09-20
US10196360B2 true US10196360B2 (en) 2019-02-05

Family

ID=58556625

Family Applications (1)

Application Number Title Priority Date Filing Date
US15/760,090 Active US10196360B2 (en) 2015-10-20 2015-10-20 Crystal forms of bedaquiline fumarate and preparation methods therefor

Country Status (6)

Country Link
US (1) US10196360B2 (fr)
EP (1) EP3366676B1 (fr)
KR (1) KR102106318B1 (fr)
CN (1) CN108349898B (fr)
RU (1) RU2018111482A (fr)
WO (1) WO2017066926A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3651736B1 (fr) * 2017-07-14 2021-06-23 Janssen Pharmaceutica NV Formulations à action prolongée
KR102303635B1 (ko) * 2020-07-01 2021-09-17 동아에스티 주식회사 (1r,2s)-1-(6-브로모-2-메톡시퀴놀린-3-일)-4-디메틸아미노-2-(1-나프틸)-1-페닐-부탄-2-올 및 이의 약제학적으로 허용 가능한 염의 제조방법
CN111606850B (zh) * 2020-07-07 2023-07-25 安徽贝克生物制药有限公司 贝达喹啉及其中间体的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050148581A1 (en) 2002-07-25 2005-07-07 Van Gestel Jozef F.E. Novel mycobacterial inhibitors
CN1976704A (zh) 2004-05-28 2007-06-06 詹森药业有限公司 取代的喹啉衍生物在治疗耐药性分枝杆菌性疾病中的用途
WO2008068231A1 (fr) 2006-12-05 2008-06-12 Janssen Pharmaceutica N.V. Sel de fumarate de (alpha s, bêta r)-6-bromo-alpha-[2-(diméthylamino)éthyl]-2-méthoxy-alpha-1-naphtalényl-bêta-phényl-3-quinoléineéthanol
WO2016058564A1 (fr) * 2014-10-16 2016-04-21 Zentiva, K.S. Sels de bédaquiline

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106279017A (zh) * 2015-05-21 2017-01-04 重庆圣华曦药业股份有限公司 贝达喹啉晶型、组合物及其制备方法
CN106316943A (zh) * 2016-07-27 2017-01-11 重庆华邦制药有限公司 富马酸贝达喹啉晶型化合物的精制方法

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050148581A1 (en) 2002-07-25 2005-07-07 Van Gestel Jozef F.E. Novel mycobacterial inhibitors
CN1671667A (zh) 2002-07-25 2005-09-21 詹森药业有限公司 喹啉衍生物及其作为分枝杆菌抑制剂的应用
CN1976704A (zh) 2004-05-28 2007-06-06 詹森药业有限公司 取代的喹啉衍生物在治疗耐药性分枝杆菌性疾病中的用途
US20070249667A1 (en) 2004-05-28 2007-10-25 Janssen Pharmaceutica N.V. Use of Substituted Quinoline Derivatives for the Treatment of Drug Resistant Mycobacterial Diseases
WO2008068231A1 (fr) 2006-12-05 2008-06-12 Janssen Pharmaceutica N.V. Sel de fumarate de (alpha s, bêta r)-6-bromo-alpha-[2-(diméthylamino)éthyl]-2-méthoxy-alpha-1-naphtalényl-bêta-phényl-3-quinoléineéthanol
CN101547904A (zh) 2006-12-05 2009-09-30 詹森药业有限公司 (αS，βR)-6-溴-α-[2-(二甲胺基)乙基]-2-甲氧基-α-1-萘基-β-苯基-3-喹啉乙醇的富马酸盐
US20100028428A1 (en) * 2006-12-05 2010-02-04 Jean Francois Alexandre Lucas Hegyi Fumarate salt of (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol
WO2016058564A1 (fr) * 2014-10-16 2016-04-21 Zentiva, K.S. Sels de bédaquiline

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
International Search Report for PCT/CN2015/092343 dated Jun. 14, 2016.

Also Published As

Publication number Publication date
EP3366676A4 (fr) 2019-06-12
KR102106318B1 (ko) 2020-05-06
CN108349898A (zh) 2018-07-31
EP3366676A1 (fr) 2018-08-29
RU2018111482A3 (fr) 2019-11-21
RU2018111482A (ru) 2019-11-21
CN108349898B (zh) 2021-03-23
EP3366676B1 (fr) 2021-05-26
WO2017066926A1 (fr) 2017-04-27
KR20180059941A (ko) 2018-06-05
US20180265473A1 (en) 2018-09-20

Similar Documents

Publication Publication Date Title
US20190337908A1 (en) Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof
US10364244B2 (en) Crystal form of pyrroloquinoline quinone sodium salt and preparation method and use thereof
US10196360B2 (en) Crystal forms of bedaquiline fumarate and preparation methods therefor
US8933114B2 (en) Polymorphic forms of asenapine maleate and processes for their preparation
EP2358658A2 (fr) Préparation de rasagiline et de ses sels
KR20150036336A (ko) 타이로신 키나제 억제제 다이말리에이트의 결정형 아이 및 그의 제조 방법
CN105801645B (zh) 制备索非布韦晶型6的方法
US20220348548A1 (en) Composition of 5-Fluorouracil and Refining Method Therefor
CN111303097B (zh) 二甲胺含笑内酯富马酸盐晶型c及其制备方法
CN109574975B (zh) 7,8-二羟基黄酮衍生物的晶型及其制备方法和应用
CN104478979A (zh) 一种无结晶水二丁酰环磷腺苷钙晶型及其制备方法和应用
CN103980166B (zh) 一种氟苯尼考的新晶型及其制备方法
US20190248773A1 (en) Process for the preparation of pure and stable crystalline raltegravir potassium form 3
US20190218184A1 (en) Novel Crystalline Form of Lenvantinib Mesylate and Process of Preparation Thereof
CN105669476A (zh) 一种盐酸多巴酚丁胺晶型及其制备方法和应用
EP2160376A2 (fr) Nouvelles formes cristallines d'atovaquone
CN106336363B (zh) 一种沙芬酰胺甲磺酸盐晶型c及其制备方法
CN107311993A (zh) 一种卡格列净的晶型ii及其制备方法
EP3002286B1 (fr) Procédé de préparation de 6-(4-chlorophénoxy)-tétrazolo[5,1-a]phtalazine polymorphe et son utilisation
US11485754B2 (en) Cyclic-di-AMP sodium salt crystal
CN107056691A (zh) 一种制备依托考昔晶型v的方法
CN107629048B (zh) 一种酪氨酸激酶抑制剂的苹果酸盐的结晶形式及其制备方法
CN106146494A (zh) 用于制备帕布昔利布a型晶的溶剂及制备方法
CN102260242B (zh) 甲磺酸伊马替尼多晶型物及其药用组合物
US20220024905A1 (en) Crystalline form of propanamide derivative and preparation method therefor

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

AS Assignment

Owner name: ZHEJIANG HISUN PHARMACEUTICAL CO., LTD., CHINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:XU, JINYI;ZHANG, LIANG;ZHANG, XIANGYANG;AND OTHERS;SIGNING DATES FROM 20180226 TO 20180306;REEL/FRAME:045290/0605

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 4